Flow Cytometry in Hematology: Principles, Gating, and Leukemia Diagnosis

Flow cytometry can characterize thousands to millions of individual cells within minutes, making it particularly useful for diseases defined by abnormal cell populations, according to the source text. In hematology, the technique determines whether an abnormal population exists, identifies its cellular lineage, evaluates its maturity, and detects antigen patterns that differ from normal cells. The diagnostic value of the test comes from the overall antigen pattern rather than an isolated list of positive and negative markers. For example, the CD5 marker is normal when expressed on T cells, but its presence on a clonal B-cell population raises a differential diagnosis for chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma.

How Laser Light and Fluorescence Sort Cellular Data

During the procedure, cells from blood, bone marrow, lymph node, cerebrospinal fluid, or other specimens are suspended in fluid and passed individually through one or more lasers. The instrument captures two broad categories of signals to characterize each sample.

Light scatter provides physical data, where forward scatter correlates roughly with cell size and side scatter reflects internal complexity or granularity. These properties help separate lymphocytes, monocytes, granulocytes, blasts, and cellular debris, although scatter alone cannot identify a malignancy.

Fluorescence provides the immunophenotype after cell suspensions are incubated with antibodies linked to fluorochromes against selected cellular antigens. As labeled cells pass through the lasers, fluorochromes emit light at characteristic wavelengths that detectors convert into electronic data. Modern multiparameter flow cytometry measures many antigens on the same cell simultaneously, allowing laboratories to test for coexpressed markers and grade staining intensities.

Gating and Panels Define Target Cell Populations

Gating defines the specific cell population that will be analyzed from a complex marrow or blood specimen, preventing interpretive mistakes such as reading percentages without a clear denominator. An initial gate often uses CD45 and side scatter to separate broad leukocyte populations before additional marker combinations narrow down the target cells.

Laboratories utilize different types of panels depending on the clinical question. Screening or orientation panels determine the nature of an abnormal population, such as the EuroFlow Acute Leukemia Orientation Tube used in suspected acute leukemia. Diagnostic characterization panels follow to define the precise phenotype once an abnormality is identified, while measurable residual disease panels utilize high sensitivity to search for very small residual abnormal populations after treatment.

Detecting Lineage in Acute Leukemia and Mature B-Cell Neoplasms

In acute leukemia, flow cytometry identifies immature blast populations using markers like CD34, CD117, TdT, and HLA-DR to characterize maturation without independently establishing lineage. Leukemic blasts frequently express antigens outside their expected lineage, such as acute myeloid leukemia aberrantly expressing CD7 or CD19, though lineage assignment relies on defined criteria rather than positive marker counts.

Specific phenotypes then guide subsequent testing or confirm diagnoses. Flow cytometry can strongly suggest acute promyelocytic leukemia, prompting confirmatory detection of the PML::RARA fusion via FISH or RT-PCR. For mature B-cell populations, surface kappa and lambda light chains assess clonality, where a marked predominance of one light chain supports a clonal process before final classification by the remaining phenotype.